Abraxis BioScience

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Retrieved on: 
Tuesday, February 7, 2023
Biology, Sequel, Small RNA, RNA-Seq, RNA, Research, High fidelity, Mass meeting, Genomics, Abraxis BioScience

MENLO PARK, Calif., Feb. 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the commencement of a program intended to expand Multiplexed Arrays Sequencing (MAS-Seq) for new assays on the Sequel II/IIe and Revio™ sequencing systems. This program builds on the successful MAS-Seq concatenation technology launched last year that enabled cost-effective single-cell isoform sequencing.

Key Points: 
  • This program builds on the successful MAS-Seq concatenation technology launched last year that enabled cost-effective single-cell isoform sequencing.
  • The MAS-Seq technology concatenates multiple shorter fragments which are then read on the system as one long HiFi read.
  • We believe that extending MAS-Seq technology to key applications such as bulk RNA sequencing and 16S rRNA will provide customers with cost-effective kitted solutions and end-to-end software.
  • We are tremendously excited to build on the momentum of MAS-Seq to open new opportunities in Bulk RNA-Seq and 16S rRNA studies for our customers."

PacBio to Report Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023

Retrieved on: 
Thursday, February 2, 2023
Abraxis BioScience, Internet, Online shopping

MENLO PARK, Calif., Feb. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, at 4:30 pm Eastern Time.

Key Points: 
  • MENLO PARK, Calif., Feb. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, at 4:30 pm Eastern Time.
  • The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ .
  • Listen live via internet or replay: https://investor.pacificbiosciences.com/
    If using the dial-in option, please dial into the call five to ten minutes prior to start time using the appropriate number above and ask to join the "PacBio Q4 Earnings Call."

Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Retrieved on: 
Wednesday, January 25, 2023
Varick Street, Telephone, Pacific Biosciences, Security (finance), Abraxis BioScience, 2nd Floor, Sale, Attention, Lexington Avenue, File, Research, Prospectus

MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share.

Key Points: 
  • MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share.
  • PacBio has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about January 27, 2023 subject to satisfaction of customary closing conditions.
  • Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus.

Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, January 24, 2023
Varick Street, Telephone, Pacific Biosciences, Security (finance), Abraxis BioScience, 2nd Floor, Sale, Attention, Lexington Avenue, File, Research, Prospectus

MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering.

Key Points: 
  • MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering.
  • PacBio also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock, at the public offering price, less underwriting discounts and commissions.
  • The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

PacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year"

Retrieved on: 
Friday, January 13, 2023
Abraxis BioScience, Vertebrate Genomes Project, Genome, DNA methylation, DNA, Nature Methods, Economics, Genomics, Science, Chemistry, Doctor of Philosophy, High fidelity, Book

MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022."

Key Points: 
  • MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022."
  • "PacBio has led a transformation of genomics by making long-read sequencing more accurate and accessible than ever with the introduction of HiFi sequencing," said Christian Henry, President and Chief Executive Officer of PacBio.
  • "Nature Methods recognizes the criticality of highly accurate long-read sequencing to continuing to advance genomic research.
  • Nature Methods cited four wish-list items which further long-read sequencing: lower cost, greater accuracy, time savings, and increased application utility.

PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022

Retrieved on: 
Monday, January 9, 2023
SBB, Gene editing, Automation, DNA, Event, Laboratory, Apple IIe, Growth, Genome, High fidelity, Investment, Conference, Genetics, PARK, Video game, Pharmaceutical industry, Sequel, Abraxis BioScience

MENLO PARK, Calif., Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today it received orders for 76 Revio systems in its fourth quarter ended December 31, 2022, making it the most successful product announcement in PacBio's history.

Key Points: 
  • PacBio commenced its beta program for Onso in the fourth quarter of 2022.
  • PacBio expects to begin taking orders this quarter and start shipping by the end of the second quarter of 2023.
  • Received orders for 96 instruments in the fourth quarter, which included orders for 76 Revio systems for delivery in 2023.
  • Placed 18 Sequel II/IIe systems during the fourth quarter compared to 48 Sequel II/IIe systems placed in the prior year quarter.

PacBio and the University of Tokyo Announce Bioinformatics Applications Collaboration

Retrieved on: 
Monday, January 9, 2023
University, Abraxis BioScience, Genome, Computational biology, Department of Neurology, Xuanwu hospital, Graduate school, Tandem, Pharmaceutical industry, Neurology

"Through this collaboration with the University of Tokyo, we plan on developing and applying new methods in the hopes of identifying genetic mutations of many diseases impacting the Japanese population," said Michael Eberle, Vice President of Computational Biology at PacBio.

Key Points: 
  • "Through this collaboration with the University of Tokyo, we plan on developing and applying new methods in the hopes of identifying genetic mutations of many diseases impacting the Japanese population," said Michael Eberle, Vice President of Computational Biology at PacBio.
  • "This will help improve our understanding of difficult genetic regions and variants that we hope will benefit the Japanese population."
  • "Collaborating with PacBio in applying advanced bioinformatics workflows should accelerate our in-progress work characterizing structural variants and making these findings more accessible to the broader scientific community.
  • We believe this collaboration will complement our previous work and help us identify many more disease-causing structural variations in the human genome," said Dr. Shoji Tsuji, a senior investigator for the University of Tokyo Hospital, Department of Neurology.

PacBio to Present at 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 28, 2022
Microbiology, Infection, Medicine, High fidelity, Abraxis BioScience, Research, Pacific Biosciences, Conference, Q&A, Pharmaceutical industry

MENLO PARK, Calif., Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events at the 41st Annual J.P. Morgan Healthcare Conference:

Key Points: 
  • MENLO PARK, Calif., Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events at the 41st Annual J.P. Morgan Healthcare Conference:
    Panel | Multiomics: Markers for Modern Medicine on Tuesday, January 10, 2023, at approximately 5:15 PM PT.
  • Company presentation and Q&A session on Wednesday, January 11, 2023, at approximately 1:30 PM PT.
  • The live webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com.
  • For more information, please visit www.pacb.com and follow @PacBio.

PacBio and Boston Children's Hospital Collaborate to Investigate Novel Variants Inaccessible by Short-Read Sequencing

Retrieved on: 
Tuesday, December 6, 2022
SBB, Genome, Security (finance), Boston Children's Hospital, Infection, High fidelity, Research, Leukemia, Patient, DNA, DNA methylation, Degenerative disease, Microbiology, Epilepsy, Genomics, Hospital, Pacific Biosciences, Congenital hearing loss, Pharmaceutical industry, Medical imaging, Abraxis BioScience

MENLO PARK, Calif., Dec. 6, 2022 /PRNewswire/ -- PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced its HiFi sequencing technology will be used in a pilot project for the Children's Rare Disease Cohorts Initiative (CRDC) at Boston Children's Hospital. Boston Children's Hospital researchers will use HiFi whole-genome sequencing (HiFi WGS) for the purpose of investigating genetic and epigenetic variants associated with rare pediatric diseases. Samples from individuals enrolled in multiple rare disease cohorts that have remained undiagnosed after short-read whole exome sequencing will be examined using HiFi WGS. The study will also explore epigenetic variation using the ability of HiFi WGS to measure DNA methylation in every sequencing run.

Key Points: 
  • Boston Children's Hospital researchers will use HiFi whole-genome sequencing (HiFi WGS) for the purpose of investigating genetic and epigenetic variants associated with rare pediatric diseases.
  • The study will also explore epigenetic variation using the ability of HiFi WGS to measure DNA methylation in every sequencing run.
  • In previous research conducted using PacBio's technology, HiFi sequencing detected more than two-fold structural variants and 200,000 more single-nucleotide variants than short-read sequencing.
  • "HiFi sequencing holds the promise to investigate parts of the genome inaccessible via other technologies," said Piotr Sliz, Vice President and Chief Research Information Officer at Boston Children's Hospital.

RNA Sequencing Services Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Health, Genetics, Other Science, Research, Science, Biotechnology, Lynx, National Institutes of Health, Sequence, Porter's five forces analysis, Abraxis BioScience, MENA, Research, RNA, NIH, Maintenance, Gene, Benchmarking, Patent, CPC, Type, Services marketing, Organization, NGS, Fine chemical, Vaccine, Antibiotics, Phosphorus, Illumina, Nanopore

The 'RNA Sequencing Services Market'' report features an extensive study of the current market landscape and future potential of the RNA sequencing services market.

Key Points: 
  • The 'RNA Sequencing Services Market'' report features an extensive study of the current market landscape and future potential of the RNA sequencing services market.
  • Currently, more than 70 companies offer services related to RNA sequencing.
  • A general overview of RNA sequencing, along with information on the key steps involved in the process, details on the various types, methods and applications of RNA sequencing, as well as the advantages and limitations associated with RNA sequencing.
  • Which type of next generation sequencing kits are being used to collect samples for RNA sequencing?